Patients with long-standing type 2 diabetes and obesity on IT can, with sufficient weight loss achieved through a low-energy TDR intervention, reduce insulin burden and improve QoL. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.